Information:
Error:
ID
13080
Description
Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02233023
Link
https://clinicaltrials.gov/show/NCT02233023
Keywords
Versions (1)
- 1/15/16 1/15/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
January 15, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Parkinson Disease NCT02233023
Eligibility Parkinson Disease NCT02233023
- StudyEvent: Eligibility
Similar models
Eligibility Parkinson Disease NCT02233023
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
parkinson's disease
Item
patients with idiopathic parkinson's disease
boolean
C0030567 (UMLS CUI [1])
parkinson treatment
Item
patients treated consecutively with either pramipexole or bromocriptine (or other dopamine agonists except ropinirole) for at least two and a half years (i.e. 30 months). interruptions of ongoing dopamine agonists treatment for less than one month per year duration are acceptable, however, interruptions within the last 6 months are not acceptable. patients currently participating in ongoing open-label extension trials with pramipexole may be included if they meet the requirement of 30 month treatment
boolean
C0074710 (UMLS CUI [1])
C0006230 (UMLS CUI [2])
C0178601 (UMLS CUI [3])
C0006230 (UMLS CUI [2])
C0178601 (UMLS CUI [3])
informed consent
Item
written informed consent in accordance with good clinical practice (gcp) and local legislation
boolean
C0021430 (UMLS CUI [1])
patients who have been treated less than two and a half years (i.e. 30 months) with their actual dopamine agonist
Item
patients who have been treated less than two and a half years (i.e. 30 months) with their actual dopamine agonist (regardless of the duration of treatment with a previous dopamine agonist)
boolean
C0178601 (UMLS CUI [1])
ropinirole
Item
patient treated with ropinirole
boolean
C0244821 (UMLS CUI [1])
hereditary retinal disease
Item
patients with a hereditary retinal disease and/or a family history of hereditary retinal disease
boolean
C0035309 (UMLS CUI [1])
drug-induced retinopathies
Item
patients with a history of drug-induced retinopathies
boolean
C0035309 (UMLS CUI [1])
diabetic retinopathy
Item
patients with a history of surgically or laser-treated diabetic retinopathy
boolean
C0011884 (UMLS CUI [1])
atypical parkinsonian syndromes
Item
patients with atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases (e.g. progressive, supranuclear palsy, multisystem atrophy)
boolean
C1868596 (UMLS CUI [1])
informed consent
Item
dementia or other disorders that could impair the signing of informed consent
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
participation in other studies
Item
patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the first visit (patients currently participating in ongoing open-label extension trials with pramipexole may be included if they meet the requirement of 30 months treatment duration
boolean
C2348568 (UMLS CUI [1])